Annette Favorite Sells 8,135 Shares of West Pharmaceutical Services (NYSE:WST) Stock

West Pharmaceutical Services, Inc. (NYSE:WST) VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the sale, the vice president owned 16,845 shares in the company, valued at approximately $5,740,944.45. This trade represents a 32.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

West Pharmaceutical Services Price Performance

WST stock opened at $345.49 on Friday. The business’s 50-day moving average is $348.46 and its two-hundred day moving average is $310.28. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market capitalization of $24.31 billion, a P/E ratio of 44.24, a P/E/G ratio of 2.41 and a beta of 1.14. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the company posted $1.84 earnings per share. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.27%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Addison Advisors LLC purchased a new stake in West Pharmaceutical Services in the second quarter valued at $28,000. Avalon Trust Co purchased a new position in shares of West Pharmaceutical Services during the second quarter worth about $28,000. Elyxium Wealth LLC purchased a new position in shares of West Pharmaceutical Services during the fourth quarter worth about $25,000. Bayban acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter worth about $27,000. Finally, DV Equities LLC acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter worth about $28,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analysts Set New Price Targets

WST has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. KeyCorp increased their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Citigroup lifted their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Evercore reiterated an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and an average target price of $373.85.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc (NYSE: WST) develops and manufactures components and systems used to package, contain and deliver injectable medicines and other healthcare products. Its customers include pharmaceutical, biotechnology and medical device companies, which use West products in drug administration and medical applications.

The company’s offerings include elastomer components such as stoppers, plungers and seals; syringe and cartridge components; vial and container closure systems; and specialized delivery systems for injectable and other complex medicines.